Atlassian Corporation Plc (NASDAQ:TEAM)
Atlassian Corporation Plc is engaged in designing, developing, licensing and maintaining of software and the provisioning of software hosting services. The Company’s products include JIRA for team planning and project management; Confluence for team content creation and sharing; HipChat for team messaging and communications; Bitbucket for team code sharing and management and JIRA Service Desk for team services and support applications. It offers tools for software developers consists of FishEye, Bamboo and SourceTree. Atlassian Corporation Plc is headquartered in Sydney, Australia.
Atlassian Corporation Plc (NASDAQ:TEAM)’s Financial Overview
Atlassian Corporation Plc (NASDAQ) declined -5.11% yesterday to close its trading session at $84.48. The company has 1 year Price Target of $91.15. Atlassian Corporation Plc has 52-Week high of $98.21 and 52-Week Low of $47.74. The stock touched its 52-Week High on 98.21 and 52-Week Low on 47.32. The stock traded with the volume of 1.2 Million shares yesterday. The firm shows the market capitalization of $20.71 Billion.
Atlassian Corporation Plc (NASDAQ) reported its last quarterly earnings on 9/29/2018 where the firm reported its Actual EPS of $0.2/share against the analyst consensus estimate of $0.19/share. The difference between the actual and expected EPS is $0.01 a share with a surprise factor of 5.3%.
The firm is trading with SMA20 of 0.63 Percent, SMA50 of 8.37 Percent and SMA200 of 16.45 percent. Atlassian Corporation Plc has P/S value of 21.86 while its P/B value stands at 27.97. Similarly, the company has Return on Assets of -18.2 percent, Return on Equity of -41.3 percent and Return on Investment of -3.5 Percent. The company shows Gross Margin and Operating Margin of 81.2 percent and -3.3 percent respectively.
The Stock currently has Analyst’ mean Recommendation of 2.1 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.
The 12 analysts offering 12-month price forecasts for Atlassian Corp PLC have a median target of 92.00, with a high estimate of 108.00 and a low estimate of 82.00. The median estimate represents a +8.90% increase from the last price of 84.48.
Atlassian Corporation Plc is estimated to report earnings on 01/17/2019. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts’ forecasts, the consensus EPS forecast for the quarter is $0.02. The reported EPS for the same quarter last year was $-0.07.
Agile Therapeutics, Inc. (NASDAQ:AGRX)
Agile Therapeutics, Inc. is a women’s health specialty pharmaceutical company. It is focused on the development and commercialization of new prescription contraceptive products. The Company’s lead product candidate is Twirla (TM) — also known as AG200-15, a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Agile Therapeutics, Inc. is headquartered in Princeton, New Jersey.
Agile Therapeutics, Inc. (NASDAQ:AGRX)’s Financial Outlook
The 3 analysts offering 12-month price forecasts for Agile Therapeutics Inc have a median target of 3.00, with a high estimate of 4.00 and a low estimate of 3.00. The median estimate represents a +305.41% increase from the last price of 0.74.
Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.
According to Zacks Investment Research, Agile Therapeutics, Inc. has a Consensus Recommendation of 1.67. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).
The Stock surged 3.5% and closed its last trading session at $0.74. The company has the market capitalization of $26.48 Million. The stock has 52-week high of $3.92 and 52-Week low of $0.23. The firm touched its 52-Week high on 3.92 and 52-Week low on 0.23. The company has volume of 195170 shares. The company has a total of 35.79 Million shares outstanding.
Agile Therapeutics, Inc. (NASDAQ) in the last quarter reported its actual EPS of $-0.11/share where the analyst estimated EPS was $-0.15/share. The difference between the actual and Estimated EPS is $0.04. This shows a surprise factor of 26.7 percent.
The company has YTD performance of 28.49 percent. Beta for Agile Therapeutics, Inc. stands at 0.01 while its ATR (average true range) is 0.08. The company has Weekly Volatility of 14.83%% and Monthly Volatility of 13.16%%.
Agile Therapeutics, Inc. has distance from 20-day Simple Moving Average (SMA20) of 5.51%, Distance from 50-Day Simple Moving Average of -7.93 percent and Distance from 200-Day Simple Moving Average of -29.24%.
The Company currently has ROA (Return on Assets) of -54.9 percent, Return on Equity (ROE) of -76.3 Percent and Return on Investment (ROI) of 0% with Gross margin of 0 percent and Operating & Profit margin of 0% and 0% respectively.